SecBot SecBot

DRTS

Alpha Tau Medical Ltd.
Nasdaq· Surgical & Medical Instruments & Apparatus· Inc. L3· CIK 0001871321 Healthcare & Medical Devices
$11.97 −1.41 (−10.54%)
Nov 16 4:00 PM ET · prev $13.38
Market cap
$1.2B
Small cap
Consensus
Buy
82% Buy or better · 11 analysts
Median target
$18.00
+50% · range $16.00–30.00
Next earnings
Nov 24
in 7 days · EPS est. −$0.15
1 year
+214.2%
from $3.81 · Nov 17
30 days
−5.2%
from $12.62
52-week range
$3.47–15.50
−23% from high · low Nov 20
Avg volume 20D
596.5K
Nov 16 spike 2.29M
Short interest
3.92M
≈4.2% of shares · +14.1%
Days to cover
8.1
at average volume
Insider net
−$1.6M
0 buyers · 1 seller · 12 mo
New fund stakes
0
Q3 2026 13F · 0 exits
SecBot read BULLISH 11 reports · 90 days
Balance 0 bearish · 6 bullish · 5 neutral oldest → newest, height = score
Avg score ·High conf. 6/11 ·Next Earnings date, Nov 24, 2026

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

Signal stack

Where each data set points today.

  • InsidersBEARISH

    1 insider sold $1.6M.

  • InstitutionsBULLISH

    Q3 2026: 15 added (0 new), 6 trimmed or exited.

  • AnalystsBULLISH

    9 of 11 rate it Buy or better. Every target is above the price.

  • EstimatesFALLING

    Current-quarter EPS estimate −$0.142 → −$0.152 over 90 days. 1 up, 3 down in 30 days.

  • Short sellersSTEADY

    Short interest +14.1% to 3.92M shares. 8.1 days to cover, ≈4.2% of shares.

  • TrendDOWNTREND

    15% below its 50-day average.

  • SocialQUIET

    Crowd 50° (neutral) this week from 3 mentions: 0 bullish, 0 bearish. No setup is alerting.

Who's buying

13F· Q3 2026
0
new positions
0
exits
FundMoveSharesValue
BlackRock, Inc.DOUBLED1,395,251$20.8M
UBS Group AGADD1,257,198$18.7M
ARK Investment Management LLCTRIM184,377$2.7M
GEODE CAPITAL MANAGEMENT, LLCDOUBLED150,916$2.3M
MORGAN STANLEYDOUBLED126,277$1.9M
Focus Partners WealthNEAR_EXIT32,265$481.1K
Squarepoint Ops LLCADD28,014$417.7K
JANE STREET GROUP, LLCTRIM26,961$402.0K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

11 analysts
Buy 82% rate it Buy or better
Strong Buy4Buy5Hold2Sell0Strong Sell0
12-month targets · 5 analysts

Price is below the lowest target. Median implies +50%.Targets as of Nov 17, 2026.

Recent actions
DateFirmActionRating
Nov 11, 2026Piper Sandler
UPGRADE
UPGRADEOverweight
Oct 20, 2026HC Wainwright & Co.
REITERATE
REITERATEBuy
Sep 3, 2026Barclays
MAINTAIN
MAINTAINOverweight
Aug 11, 2026HC Wainwright & Co.
MAINTAIN
MAINTAINBuy
Jul 22, 2026HC Wainwright & Co.
REITERATE
REITERATEBuy
Jul 16, 2026HC Wainwright & Co.
REITERATE
REITERATEBuy

Insider ledger

Form 4
$0
bought · 0 insiders
$1.6M
sold · 1 insider
DateInsiderTypeValue
Aug 21, 2026
Levy Raphi
Chief Financial Officer
Aug 21, 2026
EXERCISE$8.6K
Aug 21, 2026
Levy Raphi
Chief Financial Officer
Aug 21, 2026
SELL$43.1K
Aug 11, 2026
Levy Raphi
Chief Financial Officer
Aug 11, 2026
SELL$248.3K
Aug 11, 2026
Levy Raphi
Chief Financial Officer
Aug 11, 2026
EXERCISE$52.8K
Jul 6, 2026
Levy Raphi
Chief Financial Officer
Jul 6, 2026
EXERCISE$6.8K
Jul 6, 2026
Levy Raphi
Chief Financial Officer
Jul 6, 2026
SELL$31.8K
Jul 2, 2026
Levy Raphi
Chief Financial Officer
Jul 2, 2026
EXERCISE$53.3K
Jul 2, 2026
Levy Raphi
Chief Financial Officer
Jul 2, 2026
SELL$232.4K

Earnings setup

Estimates
Nov 24
reports in 7 days
−$0.15
EPS estimate, this quarter
−7%
estimate change, 90 days
1↑ 3↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.15-$0.16–-$0.15-3.4%$166.7K
Next Q-$0.16-$0.17–-$0.15-3.3%$333.3K
Current FY-$0.96-$1.08–-$0.55-0.8%$503.3K
Next FY-$0.54-$0.60–-$0.50-0.7%$10.7M
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Nov 16, 2026 SEC
🔒 Fresh report (last 24h), subscribers only
Nov 16, 2026 SEC
🔒 Fresh report (last 24h), subscribers only
Nov 15, 2026 Press
Alpha Tau Medical announced updated interim results from its REGAIN trial of Alpha DaRT for recurrent glioblastoma…
Impact 7/10
Nov 15, 2026 FDA
Alpha Tau Announces New Positive Interim Results from its U.S. Alpha DaRT® Recurrent Glioblastoma Trial: All Patients Treated are Alive with Median Survival Not Reached, 6.9 Months Median Follow-Up in the First Six Evaluable Patients With 100% ORR, 100% Feasibility and No Unanticipated Serious Adverse Events - Conference Call Scheduled for 8:30am ET November 16
- All eight treated brain cancer patients in the trial remain alive as of November 11, 2026; median
Nov 12, 2026 SEC
Alpha Tau Medical Ltd. filed a Form 6-K announcing a conference call and webcast on Nov. 16, 2026, to discuss new…
6-K · Impact 3/10
Oct 29, 2026 Press
Alpha Tau Medical announced that its ordinary shares will be included in the TA-90 and TA-125 indices of the Tel Aviv…
Impact 3/10
Sep 30, 2026 Inst.
BlackRock, Inc. · DOUBLED
1,395,251 shares ($20.8M)
Sep 30, 2026 Inst.
UBS Group AG · ADD
1,257,198 shares ($18.7M)

Short side

FINRA· Oct 30, 2026
3,920,240
shares short
+14.1%
vs prior settlement
8.1
days to cover
≈4.2%
of shares outstanding
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
1 drug tracked · Drug pipeline →
Upcoming
Recent
Nov 15, 2026
FDA
Alpha Tau Announces New Positive Interim Results from its U.S. Alpha DaRT® Recurrent Glioblastoma Trial: All Patients Treated are Alive with Median Survival Not Reached, 6.9 Months Median Follow-Up in the First Six Evaluable Patients With 100% ORR, 100% Feasibility and No Unanticipated Serious Adverse Events - Conference Call Scheduled for 8:30am ET November 16
- All eight treated brain cancer patients in the trial remain alive as of November 11, 2026; median overall survival has not been reached, with a…
Nov 12, 2026
Press release
Alpha Tau to Host Investor Call to Review New Data from the Alpha DaRT® Recurrent Glioblastoma REGAIN Trial
Alpha Tau to Host Investor Call to Review New Data from the Alpha DaRT® Recurrent Glioblastoma REGAIN Trial
Oct 29, 2026
Activist
Alpha Tau Announces Inclusion in the Flagship TA-90 and TA-125 Indices of the Tel Aviv Stock Exchange
Alpha Tau Announces Inclusion in the Flagship TA-90 and TA-125 Indices of the Tel Aviv Stock Exchange
Oct 22, 2026
Contract
Alpha Tau and Samsung Medical Center Sign MOU to Explore Clinical Trial of Alpha DaRT® for Pancreatic Cancer Patients in Korea
Alpha Tau and Samsung Medical Center Sign MOU to Explore Clinical Trial of Alpha DaRT® for Pancreatic Cancer Patients in Korea...
Oct 19, 2026
FDA
Alpha Tau Announces FDA Approval to Expand Alpha DaRT® U.S. Recurrent Glioblastoma REGAIN Trial; New Trial Data to be Presented at SNO 2026 Annual Meeting
Alpha Tau Announces FDA Approval to Expand Alpha DaRT® U.S. Recurrent Glioblastoma REGAIN Trial; New Trial Data to be Presented at SNO 2026 Annual…
Reddit Mentions per day, 14 days
Crowd this week 50° Neutral 0 bullish · 0 bearish
Mentions, 7 days 3 1 in posts · 2 in comments
Recent posts
Recent comments
All social signals and their track records

SecBot reports

14 filings · 11 press releases · 8 bullish · 0 bearish · 1 mixed · 5 neutral
All DRTS filing & press-release reports (25)